Loading...

David Braff

TitleRecall Faculty
InstitutionUniversity of California San Diego
DepartmentPsychiatry
Address9500 Gilman Drive #0804
La Jolla CA 92093
Phone619-543-5570
vCardDownload vCard

    Collapse Overview 
    Collapse Overview

    Biography

    David Braff, M.D. is Distinguished Professor of Psychiatry, and Director of the Schizophrenia Program at the University of California, San Diego, School of Medicine. He is also Director of the NIH-funded Consortium on the Genetics of Schizophrenia (COGS). He trained at the University of Pennsylvania, Yale University, and the University of California, San Francisco.

    Research Interests

    David Braff, M.D. is Distinguished Professor of Psychiatry, and Director of the Schizophrenia Program at the Department of Psychiatry, University of California San Diego School of Medicine. He is also Director and Lead Scientist of the NIH-funded multi-site Consortium on the Genetics of Schizophrenia (COGS). He trained at the University of Pennsylvania, Yale University, and the University of California, San Francisco.

    David Braff’s research interests have received long-term NIMH and NARSAD Distinguished Investigator funding and a special NIMH MERIT Award to extend his research as well as funding from the Veterans Administration. His interests center around 1) the identification of neurocognitive and neurophysiological biomarker deficits in psychiatric disorders (with an emphasis on schizophrenia); 2) understanding the neural circuit/substrate dysfunctions of schizophrenia patients using human and cross-species translational animal model studies; 3) using neurocognitive, imaging, information processing, and attentional dysregulation as endophenotypes in family/genetic studies; 4) utilizing translational and genetic research tools to identify the neural circuit basis and the genetic architecture of neuropsychiatric disorders such as schizophrenia; and 5) utilizing genetically and behaviorally determined, strong inference-based targets for developing efficacious antipsychotic medications and psychosocial therapies that can improve the functional outcome and quality of life of schizophrenia patients and reduce the devastating disease burden placed on them and their families by this “no fault” clinical brain disorder.

    David Braff has published over 250 articles and 300 reviews, book chapters and abstracts. He has received special recognition from the Institute for Scientific Information (ISI) as being in the top half of 1% of most highly cited neuropsychiatric researchers. In addition, he has been the Attending Physician for over 10,000 patients with schizophrenia and other serious mental disorders, and has trained many researchers and clinicians. Dr. Braff has served as Councilor, Executive Secretary and President of the Society of Biological Psychiatry (SOBP), and as a Councilor and President of the American College of Neuropsychopharmacology (ACNP), 2 world leading neuropsychiatric research societies. He has consulted to the Diagnostic and Statistical Manual (DSM IV and V) Committee of the APA, and Expert Treatment Committee of the American Psychiatric Association (APA). He is the Co-Chair of the Executive Committee and Director of the Clinical Neurosciences and Genomic Unit at the Veterans Administration VISN 22 Mental Illness, Research and Clinical Center (MIRECC) program in the Southwest United States which investigates psychosis and its treatment. He has also been a key figure in advancing the Mission of the International Congress on Schizophrenia Research (ICOSR) and liaisoned USA-Russia and USA-China cultural and grant cooperative projects. He served for 15 years as President of the campus-wide UCSD Faculty Association.

    David Braff has received numerous Grants, Awards, and Prizes. A Fellow of the American Psychiatric Association (APA), Dr. Braff received the Kempf Research Prize and Marmor Award for excellence in biopsychosocial research from the APA, as well as the Gold Medal for lifetime research accomplishments from the SOBP, and the Warren Award for schizophrenia research from the ICOSR. He received the George Thompson Award from the SOBP for service to the field, the Dean Award for Schizophrenia Research Excellence from the American College of Psychiatrists (ACP) as well as Gold Medal for psychiatric research from Society of Biological Psychiatry with other awards. He has been selected by his peers as one of the “Best Doctors” in the United States and in San Diego. He serves on many national and international committees and societies, such as the Executive Committee of the MATRICS Project of the NIMH, which identified novel cognitive targets for antipsychotic medications, and other NIMH advisory committees that focus on issues such as the design and conduct of large clinical treatment trials. Dr. Braff is on the Editorial Boards of the Archives of General Psychiatry and five other journals and reviews manuscripts for over 20 Top Journals. He has lectured nationally and internationally on many topics in neuropsychiatric science and practice, and is recognized as a leader of the international neuropsychiatric community.


    Collapse Research 
    Collapse Research Activities and Funding
    2/5-Gentics of Transcriptional Endophenotypes for Schizophrenia
    NIH/NIMH R01MH093533Apr 15, 2012 - Mar 31, 2015
    Role: Principal Investigator
    5/5:Family-Based Genome-Wide Methylation Scan in Neurocognition and Schizophrenia
    NIH/NIMH RC2MH089984Sep 30, 2009 - Aug 31, 2011
    Role: Principal Investigator
    4/4-A Genomic Approach to Schizophrenia
    NIH/NIMH R01MH084071Apr 16, 2009 - Jan 31, 2014
    Role: Principal Investigator
    5/5: A Genome-wide Methylation Scan for Epigenetic Contributions to Schizophrenia
    NIH/NIMH U01MH085265Sep 30, 2008 - May 31, 2014
    Role: Principal Investigator
    1/6-The Genetics of Endophenotypes and Schizophrenia
    NIH/NIMH R01MH065571Apr 4, 2003 - Jan 31, 2014
    Role: Principal Investigator
    Gating and Inhibiting in Schizophrenia
    NIH/NIMH R01MH042228Jan 1, 1987 - Apr 30, 2016
    Role: Principal Investigator
    SENSORY GATING AND HABITUATION IN SCHIZOPHRENIA
    NIH/NIMH R37MH042228Jan 1, 1987 - Apr 16, 2003
    Role: Principal Investigator
    General Clinical Research Center
    NIH/NCRR M01RR000827Mar 1, 1974 - Nov 30, 2010
    Role: Co-Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Thomas ML, Bismark AW, Joshi YB, Tarasenko M, Treichler EBH, Hochberger WC, Zhang W, Nungaray J, Sprock J, Cardoso L, Tiernan K, Attarha M, Braff DL, Vinogradov S, Swerdlow N, Light GA. Targeted cognitive training improves auditory and verbal outcomes among treatment refractory schizophrenia patients mandated to residential care. Schizophr Res. 2018 Jul 25. PMID: 30055883.
      View in: PubMed
    2. Swerdlow NR, Light GA, Thomas ML, Sprock J, Calkins ME, Green MF, Greenwood TA, Gur RE, Gur RC, Lazzeroni LC, Nuechterlein KH, Radant AD, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Sugar CA, Tsuang DW, Tsuang MT, Turetsky BI, Braff DL. Deficient prepulse inhibition in schizophrenia in a multi-site cohort: Internal replication and extension. Schizophr Res. 2017 May 23. PMID: 28549722.
      View in: PubMed
    3. Perez VB, Tarasenko M, Miyakoshi M, Pianka ST, Makeig SD, Braff DL, Swerdlow NR, Light GA. Mismatch Negativity is a Sensitive and Predictive Biomarker of Perceptual Learning During Auditory Cognitive Training in Schizophrenia. Neuropsychopharmacology. 2017 Oct; 42(11):2206-2213. PMID: 28139679.
      View in: PubMed
    4. Thomas ML, Green MF, Hellemann G, Sugar CA, Tarasenko M, Calkins ME, Greenwood TA, Gur RE, Gur RC, Lazzeroni LC, Nuechterlein KH, Radant AD, Seidman LJ, Shiluk AL, Siever LJ, Silverman JM, Sprock J, Stone WS, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Braff DL, Light GA. Modeling Deficits From Early Auditory Information Processing to Psychosocial Functioning in Schizophrenia. JAMA Psychiatry. 2017 Jan 01; 74(1):37-46. PMID: 27926742.
      View in: PubMed
    5. Braff DL, Tamminga CA. Endophenotypes, Epigenetics, Polygenicity and More: Irv Gottesman's Dynamic Legacy. Schizophr Bull. 2017 01; 43(1):10-16. PMID: 27872267.
      View in: PubMed
    6. Swerdlow NR, Braff DL, Geyer MA. Sensorimotor gating of the startle reflex: what we said 25 years ago, what has happened since then, and what comes next. J Psychopharmacol. 2016 11; 30(11):1072-1081. PMID: 27539931.
      View in: PubMed
    7. Krystal JH, Abi-Dargham A, Akbarian S, Arnsten AFT, Barch DM, Bearden CE, Braff DL, Brown ES, Bullmore ET, Carlezon WA, Carter CS, Cook EH, Daskalakis ZJ, DiLeone RJ, Duman RS, Grace AA, Hariri AR, Harrison PJ, Hiroi N, Kenny PJ, Kleinman JE, Krystal AD, Lewis DA, Lipska BK, Marder SR, Mason GF, Mathalon DH, McClung CA, McDougle CJ, McIntosh AM, McMahon FJ, Mirnics K, Monteggia LM, Narendran R, Nestler EJ, Neumeister A, O'Donovan MC, Öngür D, Pariante CM, Paulus MP, Pearlson G, Phillips ML, Pine DS, Pizzagalli DA, Pletnikov MV, Ragland JD, Rapoport JL, Ressler KJ, Russo SJ, Sanacora G, Sawa A, Schatzberg AF, Shaham Y, Shamay-Tsoory SG, Sklar P, State MW, Stein MB, Strakowski SM, Taylor SF, Turecki G, Turetsky BI, Weissman MM, Zachariou V, Zarate CA, Zubieta JK. Constance E. Lieber, Theodore R. Stanley, and the Enduring Impact of Philanthropy on Psychiatry Research. Biol Psychiatry. 2016 07 15; 80(2):84-86. PMID: 27346079.
      View in: PubMed
    8. Montano C, Taub MA, Jaffe A, Briem E, Feinberg JI, Trygvadottir R, Idrizi A, Runarsson A, Berndsen B, Gur RC, Moore TM, Perry RT, Fugman D, Sabunciyan S, Yolken RH, Hyde TM, Kleinman JE, Sobell JL, Pato CN, Pato MT, Go RC, Nimgaonkar V, Weinberger DR, Braff D, Gur RE, Fallin MD, Feinberg AP. Association of DNA Methylation Differences With Schizophrenia in an Epigenome-Wide Association Study. JAMA Psychiatry. 2016 May 01; 73(5):506-14. PMID: 27074206.
      View in: PubMed
    9. Millard SP, Shofer J, Braff D, Calkins M, Cadenhead K, Freedman R, Green MF, Greenwood TA, Gur R, Gur R, Lazzeroni LC, Light GA, Olincy A, Nuechterlein K, Seidman L, Siever L, Silverman J, Stone WS, Sprock J, Sugar CA, Swerdlow NR, Tsuang M, Turetsky B, Radant A, Tsuang DW. Prioritizing schizophrenia endophenotypes for future genetic studies: An example using data from the COGS-1 family study. Schizophr Res. 2016 07; 174(1-3):1-9. PMID: 27132484; PMCID: PMC4912929 [Available on 07/01/17].
    10. Tarasenko M, Perez VB, Pianka ST, Vinogradov S, Braff DL, Swerdlow NR, Light GA. Measuring the capacity for auditory system plasticity: An examination of performance gains during initial exposure to auditory-targeted cognitive training in schizophrenia. Schizophr Res. 2016 Apr; 172(1-3):123-30. PMID: 26851143.
      View in: PubMed
    11. Greenwood TA, Lazzeroni LC, Calkins ME, Freedman R, Green MF, Gur RE, Gur RC, Light GA, Nuechterlein KH, Olincy A, Radant AD, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Sugar CA, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Braff DL. Genetic assessment of additional endophenotypes from the Consortium on the Genetics of Schizophrenia Family Study. Schizophr Res. 2016 Jan; 170(1):30-40. PMID: 26597662; PMCID: PMC4707095 [Available on 01/01/17].
    12. Greenwood TA, Light GA, Swerdlow NR, Calkins ME, Green MF, Gur RE, Gur RC, Lazzeroni LC, Nuechterlein KH, Olincy A, Radant AD, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Sugar CA, Tsuang DW, Tsuang MT, Turetsky BI, Freedman R, Braff DL. Gating Deficit Heritability and Correlation With Increased Clinical Severity in Schizophrenia Patients With Positive Family History. Am J Psychiatry. 2016 Apr 01; 173(4):385-91. PMID: 26441157; PMCID: PMC4933520 [Available on 04/01/17].
    13. Tsang J, Fullard JF, Giakoumaki SG, Katsel P, Eirini Karagiorga V, Greenwood TA, Braff DL, Siever LJ, Bitsios P, Haroutunian V, Roussos P. Erratum: The relationship between dopamine receptor D1 and cognitive performance. NPJ Schizophr. 2015; 1:15018. PMID: 27336628; PMCID: PMC4849446.
    14. Gur RC, Braff DL, Calkins ME, Dobie DJ, Freedman R, Green MF, Greenwood TA, Lazzeroni LC, Light GA, Nuechterlein KH, Olincy A, Radant AD, Seidman LJ, Siever LJ, Silverman JM, Sprock J, Stone WS, Sugar CA, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Gur RE. Neurocognitive performance in family-based and case-control studies of schizophrenia. Schizophr Res. 2015 Apr; 163(1-3):17-23. PMID: 25432636; PMCID: PMC4441547.
    15. Braff DL. The importance of endophenotypes in schizophrenia research. Schizophr Res. 2015 Apr; 163(1-3):1-8. PMID: 25795083.
      View in: PubMed
    16. Nuechterlein KH, Green MF, Calkins ME, Greenwood TA, Gur RE, Gur RC, Lazzeroni LC, Light GA, Radant AD, Seidman LJ, Siever LJ, Silverman JM, Sprock J, Stone WS, Sugar CA, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Braff DL. Attention/vigilance in schizophrenia: performance results from a large multi-site study of the Consortium on the Genetics of Schizophrenia (COGS). Schizophr Res. 2015 Apr; 163(1-3):38-46. PMID: 25749017; PMCID: PMC4382444.
    17. Tsang J, Fullard JF, Giakoumaki SG, Katsel P, Katsel P, Karagiorga VE, Greenwood TA, Braff DL, Siever LJ, Bitsios P, Haroutunian V, Roussos P. The relationship between dopamine receptor D1 and cognitive performance. NPJ Schizophr. 2015; 1:14002. PMID: 27336024; PMCID: PMC4849437.
    18. Seidman LJ, Hellemann G, Nuechterlein KH, Greenwood TA, Braff DL, Cadenhead KS, Calkins ME, Freedman R, Gur RE, Gur RC, Lazzeroni LC, Light GA, Olincy A, Radant AD, Siever LJ, Silverman JM, Sprock J, Stone WS, Sugar C, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Green MF. Factor structure and heritability of endophenotypes in schizophrenia: findings from the Consortium on the Genetics of Schizophrenia (COGS-1). Schizophr Res. 2015 Apr; 163(1-3):73-9. PMID: 25682549.
      View in: PubMed
    19. Radant AD, Millard SP, Braff DL, Calkins ME, Dobie DJ, Freedman R, Green MF, Greenwood TA, Gur RE, Gur RC, Lazzeroni LC, Light GA, Meichle SP, Nuechterlein KH, Olincy A, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Swerdlow NR, Sugar CA, Tsuang MT, Turetsky BI, Tsuang DW. Robust differences in antisaccade performance exist between COGS schizophrenia cases and controls regardless of recruitment strategies. Schizophr Res. 2015 Apr; 163(1-3):47-52. PMID: 25553977; PMCID: PMC4382408.
    20. Stone WS, Mesholam-Gately RI, Braff DL, Calkins ME, Freedman R, Green MF, Greenwood TA, Gur RE, Gur RC, Lazzeroni LC, Light GA, Nuechterlein KH, Olincy A, Radant AD, Siever LJ, Silverman JM, Sprock J, Sugar CA, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Seidman LJ. California Verbal Learning Test-II performance in schizophrenia as a function of ascertainment strategy: comparing the first and second phases of the Consortium on the Genetics of Schizophrenia (COGS). Schizophr Res. 2015 Apr; 163(1-3):32-7. PMID: 25497440.
      View in: PubMed
    21. Braff DL. Genomic substrates of neurophysiological endophenotypes: where we've been and where we're going. Psychophysiology. 2014 Dec; 51(12):1323-4. PMID: 25387712.
      View in: PubMed
    22. Braff D. Enoch Callaway. Neuropsychopharmacology. 2014 Dec; 39(13):3125. PMID: 25381704; PMCID: PMC4229586.
    23. van Tricht MJ, Bour LJ, Koelman JH, Derks EM, Braff DL, de Wilde OM, Boerée T, Linszen DH, de Haan L, Nieman DH. Qualitative and quantitative aspects of information processing in first psychosis: latent class analyses in patients, at-risk subjects, and controls. Psychophysiology. 2015 Apr; 52(4):585-93. PMID: 25376718.
      View in: PubMed
    24. Swerdlow NR, Gur RE, Braff DL. Consortium on the Genetics of Schizophrenia (COGS) assessment of endophenotypes for schizophrenia: an introduction to this Special Issue of Schizophrenia Research. Schizophr Res. 2015 Apr; 163(1-3):9-16. PMID: 25454799; PMCID: PMC4382419.
    25. Light GA, Swerdlow NR, Thomas ML, Calkins ME, Green MF, Greenwood TA, Gur RE, Gur RC, Lazzeroni LC, Nuechterlein KH, Pela M, Radant AD, Seidman LJ, Sharp RF, Siever LJ, Silverman JM, Sprock J, Stone WS, Sugar CA, Tsuang DW, Tsuang MT, Braff DL, Turetsky BI. Validation of mismatch negativity and P3a for use in multi-site studies of schizophrenia: characterization of demographic, clinical, cognitive, and functional correlates in COGS-2. Schizophr Res. 2015 Apr; 163(1-3):63-72. PMID: 25449710; PMCID: PMC4382452.
    26. Tarasenko MA, Swerdlow NR, Makeig S, Braff DL, Light GA. The auditory brain-stem response to complex sounds: a potential biomarker for guiding treatment of psychosis. Front Psychiatry. 2014; 5:142. PMID: 25352811; PMCID: PMC4195270.
    27. Turetsky BI, Dress EM, Braff DL, Calkins ME, Green MF, Greenwood TA, Gur RE, Gur RC, Lazzeroni LC, Nuechterlein KH, Radant AD, Seidman LJ, Siever LJ, Silverman JM, Sprock J, Stone WS, Sugar CA, Swerdlow NR, Tsuang DW, Tsuang MT, Light G. The utility of P300 as a schizophrenia endophenotype and predictive biomarker: clinical and socio-demographic modulators in COGS-2. Schizophr Res. 2015 Apr; 163(1-3):53-62. PMID: 25306203; PMCID: PMC4382423.
    28. Rissling AJ, Miyakoshi M, Sugar CA, Braff DL, Makeig S, Light GA. Cortical substrates and functional correlates of auditory deviance processing deficits in schizophrenia. Neuroimage Clin. 2014; 6:424-37. PMID: 25379456.
      View in: PubMed
    29. Lee J, Green MF, Calkins ME, Greenwood TA, Gur RE, Gur RC, Lazzeroni LC, Light GA, Nuechterlein KH, Radant AD, Seidman LJ, Siever LJ, Silverman JM, Sprock J, Stone WS, Sugar CA, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Braff DL. Verbal working memory in schizophrenia from the Consortium on the Genetics of Schizophrenia (COGS) study: the moderating role of smoking status and antipsychotic medications. Schizophr Res. 2015 Apr; 163(1-3):24-31. PMID: 25248939; PMCID: PMC4368500.
    30. Light G, Greenwood TA, Swerdlow NR, Calkins ME, Freedman R, Green MF, Gur RE, Gur RC, Lazzeroni LC, Nuechterlein KH, Olincy A, Radant AD, Seidman LJ, Siever LJ, Silverman JM, Sprock J, Stone WS, Sugar CA, Tsuang DW, Tsuang MT, Turetsky BI, Braff DL. Comparison of the heritability of schizophrenia and endophenotypes in the COGS-1 family study. Schizophr Bull. 2014 Nov; 40(6):1404-11. PMID: 24903414; PMCID: PMC4193725.
    31. Schmeidler J, Lazzeroni LC, Swerdlow NR, Ferreira RP, Braff DL, Calkins ME, Cadenhead KS, Freedman R, Green MF, Greenwood TA, Gur RE, Gur RC, Light GA, Olincy A, Nuechterlein KH, Radant AD, Seidman LJ, Siever LJ, Stone WS, Sprock J, Sugar CA, Tsuang DW, Tsuang MT, Turetsky BI, Silverman JM. Paternal age of schizophrenia probands and endophenotypic differences from unaffected siblings. Psychiatry Res. 2014 Sep 30; 219(1):67-71. PMID: 24913833; PMCID: PMC4110721.
    32. Tsuang D, Esterberg M, Braff D, Calkins M, Cadenhead K, Dobie D, Freedman R, Green MF, Greenwood T, Gur R, Gur R, Horan W, Lazzeroni LC, Light GA, Millard SP, Olincy A, Nuechterlein K, Seidman L, Siever L, Silverman J, Stone W, Sprock J, Sugar C, Swerdlow N, Tsuang M, Turetsky B, Radant A. Is there an association between advanced paternal age and endophenotype deficit levels in schizophrenia? PLoS One. 2014; 9(2):e88379. PMID: 24523888; PMCID: PMC3921166.
    33. Swerdlow NR, Light GA, Sprock J, Calkins ME, Green MF, Greenwood TA, Gur RE, Gur RC, Lazzeroni LC, Nuechterlein KH, Radant AD, Ray A, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Sugar CA, Tsuang DW, Tsuang MT, Turetsky BI, Braff DL. Deficient prepulse inhibition in schizophrenia detected by the multi-site COGS. Schizophr Res. 2014 Feb; 152(2-3):503-12. PMID: 24405980; PMCID: PMC3960985.
    34. Perez VB, Swerdlow NR, Braff DL, Näätänen R, Light GA. Using biomarkers to inform diagnosis, guide treatments and track response to interventions in psychotic illnesses. Biomark Med. 2014; 8(1):9-14. PMID: 24325220; PMCID: PMC4043396.
    35. Braff L, Braff DL. The neuropsychiatric translational revolution: still very early and still very challenging. JAMA Psychiatry. 2013 Aug; 70(8):777-9. PMID: 23739986; PMCID: PMC4018228.
    36. Gulsuner S, Walsh T, Watts AC, Lee MK, Thornton AM, Casadei S, Rippey C, Shahin H. Spatial and temporal mapping of de novo mutations in schizophrenia to a fetal prefrontal cortical network. Cell. 2013 Aug 01; 154(3):518-29. PMID: 23911319; PMCID: PMC3894107.
    37. Braff DL, Ryan J, Rissling AJ, Carpenter WT. Lack of use in the literature from the last 20 years supports dropping traditional schizophrenia subtypes from DSM-5 and ICD-11. Schizophr Bull. 2013 Jul; 39(4):751-3. PMID: 23674819; PMCID: PMC3686462.
    38. Greenwood TA, Swerdlow NR, Gur RE, Cadenhead KS, Calkins ME, Dobie DJ, Freedman R, Green MF, Gur RC, Lazzeroni LC, Nuechterlein KH, Olincy A, Radant AD, Ray A, Schork NJ, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Sugar CA, Tsuang DW, Tsuang MT, Turetsky BI, Light GA, Braff DL. Genome-wide linkage analyses of 12 endophenotypes for schizophrenia from the Consortium on the Genetics of Schizophrenia. Am J Psychiatry. 2013 May; 170(5):521-32. PMID: 23511790; PMCID: PMC3878873.
    39. Rissling AJ, Park SH, Young JW, Rissling MB, Sugar CA, Sprock J, Mathias DJ, Pela M, Sharp RF, Braff DL, Light GA. Demand and modality of directed attention modulate "pre-attentive" sensory processes in schizophrenia patients and nonpsychiatric controls. Schizophr Res. 2013 May; 146(1-3):326-35. PMID: 23490760.
      View in: PubMed
    40. Calkins ME, Ray A, Gur RC, Freedman R, Green MF, Greenwood TA, Light GA, Nuechterlein KH, Olincy A, Radant AD, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Sugar C, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Braff DL, Lazzeroni LC, Gur RE. Sex differences in familiality effects on neurocognitive performance in schizophrenia. Biol Psychiatry. 2013 May 15; 73(10):976-84. PMID: 23395246; PMCID: PMC3954126.
    41. Takahashi H, Rissling AJ, Pascual-Marqui R, Kirihara K, Pela M, Sprock J, Braff DL, Light GA. Neural substrates of normal and impaired preattentive sensory discrimination in large cohorts of nonpsychiatric subjects and schizophrenia patients as indexed by MMN and P3a change detection responses. Neuroimage. 2013 Feb 01; 66:594-603. PMID: 23085112; PMCID: PMC3652903.
    42. Light GA, Swerdlow NR, Rissling AJ, Radant A, Sugar CA, Sprock J, Pela M, Geyer MA, Braff DL. Characterization of neurophysiologic and neurocognitive biomarkers for use in genomic and clinical outcome studies of schizophrenia. PLoS One. 2012; 7(7):e39434. PMID: 22802938.
      View in: PubMed
    43. Rissling AJ, Braff DL, Swerdlow NR, Hellemann G, Rassovsky Y, Sprock J, Pela M, Light GA. Disentangling early sensory information processing deficits in schizophrenia. Clin Neurophysiol. 2012 Oct; 123(10):1942-9. PMID: 22608970; PMCID: PMC3436955.
    44. Kirihara K, Rissling AJ, Swerdlow NR, Braff DL, Light GA. Hierarchical organization of gamma and theta oscillatory dynamics in schizophrenia. Biol Psychiatry. 2012 May 15; 71(10):873-80. PMID: 22361076.
      View in: PubMed
    45. Greenwood TA, Light GA, Swerdlow NR, Radant AD, Braff DL. Association analysis of 94 candidate genes and schizophrenia-related endophenotypes. PLoS One. 2012; 7(1):e29630. PMID: 22253750; PMCID: PMC3258248.
    46. Greenwood TA, Lazzeroni LC, Murray SS, Cadenhead KS, Calkins ME, Dobie DJ, Green MF, Gur RE, Gur RC, Hardiman G, Kelsoe JR, Leonard S, Light GA, Nuechterlein KH, Olincy A, Radant AD, Schork NJ, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Freedman R, Braff DL. Analysis of 94 candidate genes and 12 endophenotypes for schizophrenia from the Consortium on the Genetics of Schizophrenia. Am J Psychiatry. 2011 Sep; 168(9):930-46. PMID: 21498463; PMCID: PMC3751972.
    47. Braff DL. Gating in schizophrenia: from genes to cognition (to real world function?). Biol Psychiatry. 2011 Mar 01; 69(5):395-6. PMID: 21316513.
      View in: PubMed
    48. Stone WS, Giuliano AJ, Tsuang MT, Braff DL, Cadenhead KS, Calkins ME, Dobie DJ, Faraone SV, Freedman R, Green MF, Greenwood TA, Gur RE, Gur RC, Light GA, Mintz J, Nuechterlein KH, Olincy A, Radant AD, Roe AH, Schork NJ, Siever LJ, Silverman JM, Swerdlow NR, Thomas AR, Tsuang DW, Turetsky BI, Seidman LJ. Group and site differences on the California Verbal Learning Test in persons with schizophrenia and their first-degree relatives: findings from the Consortium on the Genetics of Schizophrenia (COGS). Schizophr Res. 2011 May; 128(1-3):102-10. PMID: 21288694.
      View in: PubMed
    49. Rissling AJ, Makeig S, Braff DL, Light GA. Neurophysiologic markers of abnormal brain activity in schizophrenia. Curr Psychiatry Rep. 2010 Dec; 12(6):572-8. PMID: 20857348; PMCID: PMC2965365.
    50. Williams LE, Ramachandran VS, Hubbard EM, Braff DL, Light GA. Superior size-weight illusion performance in patients with schizophrenia: evidence for deficits in forward models. Schizophr Res. 2010 Aug; 121(1-3):101-6. PMID: 19931421; PMCID: PMC2910228.
    51. Light GA, Williams LE, Minow F, Sprock J, Rissling A, Sharp R, Swerdlow NR, Braff DL. Electroencephalography (EEG) and event-related potentials (ERPs) with human participants. Curr Protoc Neurosci. 2010 Jul; Chapter 6:Unit 6.25.1-24. PMID: 20578033.
      View in: PubMed
    52. Williams LE, Light GA, Braff DL, Ramachandran VS. Reduced multisensory integration in patients with schizophrenia on a target detection task. Neuropsychologia. 2010 Aug; 48(10):3128-36. PMID: 20600181; PMCID: PMC2915827.
    53. Olincy A, Braff DL, Adler LE, Cadenhead KS, Calkins ME, Dobie DJ, Green MF, Greenwood TA, Gur RE, Gur RC, Light GA, Mintz J, Nuechterlein KH, Radant AD, Schork NJ, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Wagner BD, Freedman R. Inhibition of the P50 cerebral evoked response to repeated auditory stimuli: results from the Consortium on Genetics of Schizophrenia. Schizophr Res. 2010 Jun; 119(1-3):175-82. PMID: 20382002; PMCID: PMC3688282.
    54. Radant AD, Dobie DJ, Calkins ME, Olincy A, Braff DL, Cadenhead KS, Freedman R, Green MF, Greenwood TA, Gur RE, Gur RC, Light GA, Meichle SP, Millard SP, Mintz J, Nuechterlein KH, Schork NJ, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Swerdlow NR, Tsuang MT, Turetsky BI, Tsuang DW. Antisaccade performance in schizophrenia patients, their first-degree biological relatives, and community comparison subjects: data from the COGS study. Psychophysiology. 2010 Sep; 47(5):846-56. PMID: 20374545; PMCID: PMC4176871.
    55. Braff DL. Prepulse inhibition of the startle reflex: a window on the brain in schizophrenia. Curr Top Behav Neurosci. 2010; 4:349-71. PMID: 21312406.
      View in: PubMed
    56. Kiang M, Braff DL, Sprock J, Light GA. The relationship between preattentive sensory processing deficits and age in schizophrenia patients. Clin Neurophysiol. 2009 Nov; 120(11):1949-57. PMID: 19786365; PMCID: PMC2902236.
    57. Nasrallah HA, Keshavan MS, Benes FM, Braff DL, Green AI, Gur RE, Kane JM, Perkins DO, Weiden PJ, Weinberger DR, Correll CU. Proceedings and data from The Schizophrenia Summit: a critical appraisal to improve the management of Schizophrenia. J Clin Psychiatry. 2009; 70 Suppl 1:4-46. PMID: 19292973.
      View in: PubMed
    58. Turetsky BI, Greenwood TA, Olincy A, Radant AD, Braff DL, Cadenhead KS, Dobie DJ, Freedman R, Green MF, Gur RE, Gur RC, Light GA, Mintz J, Nuechterlein KH, Schork NJ, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Swerdlow NR, Tsuang DW, Tsuang MT, Calkins ME. Abnormal auditory N100 amplitude: a heritable endophenotype in first-degree relatives of schizophrenia probands. Biol Psychiatry. 2008 Dec 15; 64(12):1051-9. PMID: 18701089; PMCID: PMC2653714.
    59. Braff DL, Freedman R. Clinically responsible genetic testing in neuropsychiatric patients: a bridge too far and too soon. Am J Psychiatry. 2008 Aug; 165(8):952-5. PMID: 18676598.
      View in: PubMed
    60. Swerdlow NR, Weber M, Qu Y, Light GA, Braff DL. Realistic expectations of prepulse inhibition in translational models for schizophrenia research. Psychopharmacology (Berl). 2008 Aug; 199(3):331-88. PMID: 18568339; PMCID: PMC2771731.
    61. Krystal JH, Carter CS, Geschwind D, Manji HK, March JS, Nestler EJ, Zubieta JK, Charney DS, Goldman D, Gur RE, Lieberman JA, Roy-Byrne P, Rubinow DR, Anderson SA, Barondes S, Berman KF, Blair J, Braff DL, Brown ES, Calabrese JR, Carlezon WA, Cook EH, Davidson RJ, Davis M, Desimone R, Drevets WC, Duman RS, Essock SM, Faraone SV, Freedman R, Friston KJ, Gelernter J, Geller B, Gill M, Gould E, Grace AA, Grillon C, Gueorguieva R, Hariri AR, Innis RB, Jones EG, Kleinman JE, Koob GF, Krystal AD, Leibenluft E, Levinson DF, Levitt PR, Lewis DA, Liberzon I, Lipska BK, Marder SR, Markou A, Mason GF, McDougle CJ, McEwen BS, McMahon FJ, Meaney MJ, Meltzer HY, Merikangas KR, Meyer-Lindenberg A, Mirnics K, Monteggia LM, Neumeister A, O'Brien CP, Owen MJ, Pine DS, Rapoport JL, Rauch SL, Robbins TW, Rosenbaum JF, Rosenberg DR, Ross CA, Rush AJ, Sackeim HA, Sanacora G, Schatzberg AF, Shaham Y, Siever LJ, Sunderland T, Tecott LH, Thase ME, Todd RD, Weissman MM, Yehuda R, Yoshikawa T, Young EA, McCandless R. It is time to take a stand for medical research and against terrorism targeting medical scientists. Biol Psychiatry. 2008 Apr 15; 63(8):725-7. PMID: 18371494.
      View in: PubMed
    62. Horan WP, Braff DL, Nuechterlein KH, Sugar CA, Cadenhead KS, Calkins ME, Dobie DJ, Freedman R, Greenwood TA, Gur RE, Gur RC, Light GA, Mintz J, Olincy A, Radant AD, Schork NJ, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Green MF. Verbal working memory impairments in individuals with schizophrenia and their first-degree relatives: findings from the Consortium on the Genetics of Schizophrenia. Schizophr Res. 2008 Aug; 103(1-3):218-28. PMID: 18406578; PMCID: PMC2529172.
    63. Braff DL, Greenwood TA, Swerdlow NR, Light GA, Schork NJ. Advances in endophenotyping schizophrenia. World Psychiatry. 2008 Feb; 7(1):11-8. PMID: 18458787; PMCID: PMC2359727.
    64. Kiang M, Kutas M, Light GA, Braff DL. An event-related brain potential study of direct and indirect semantic priming in schizophrenia. Am J Psychiatry. 2008 Jan; 165(1):74-81. PMID: 18056222.
      View in: PubMed
    65. Greenwood TA, Braff DL, Light GA, Cadenhead KS, Calkins ME, Dobie DJ, Freedman R, Green MF, Gur RE, Gur RC, Mintz J, Nuechterlein KH, Olincy A, Radant AD, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Schork NJ. Initial heritability analyses of endophenotypic measures for schizophrenia: the consortium on the genetics of schizophrenia. Arch Gen Psychiatry. 2007 Nov; 64(11):1242-50. PMID: 17984393.
      View in: PubMed
    66. Sergi MJ, Green MF, Widmark C, Reist C, Erhart S, Braff DL, Kee KS, Marder SR, Mintz J. Social cognition [corrected] and neurocognition: effects of risperidone, olanzapine, and haloperidol. Am J Psychiatry. 2007 Oct; 164(10):1585-92. PMID: 17898351.
      View in: PubMed
    67. Light GA, Swerdlow NR, Braff DL. Preattentive sensory processing as indexed by the MMN and P3a brain responses is associated with cognitive and psychosocial functioning in healthy adults. J Cogn Neurosci. 2007 Oct; 19(10):1624-32. PMID: 18271737; PMCID: PMC2562660.
    68. Wynn JK, Green MF, Sprock J, Light GA, Widmark C, Reist C, Erhart S, Marder SR, Mintz J, Braff DL. Effects of olanzapine, risperidone and haloperidol on prepulse inhibition in schizophrenia patients: a double-blind, randomized controlled trial. Schizophr Res. 2007 Sep; 95(1-3):134-42. PMID: 17662577; PMCID: PMC2716219.
    69. Kiang M, Light GA, Prugh J, Coulson S, Braff DL, Kutas M. Cognitive, neurophysiological, and functional correlates of proverb interpretation abnormalities in schizophrenia. J Int Neuropsychol Soc. 2007 Jul; 13(4):653-63. PMID: 17521483.
      View in: PubMed
    70. Braff D, Schork NJ, Gottesman II. Endophenotyping schizophrenia. Am J Psychiatry. 2007 May; 164(5):705-7. PMID: 17475726.
      View in: PubMed
    71. Kiang M, Kutas M, Light GA, Braff DL. Electrophysiological insights into conceptual disorganization in schizophrenia. Schizophr Res. 2007 May; 92(1-3):225-36. PMID: 17383161; PMCID: PMC3974604.
    72. Swerdlow NR, Sprock J, Light GA, Cadenhead K, Calkins ME, Dobie DJ, Freedman R, Green MF, Greenwood TA, Gur RE, Mintz J, Olincy A, Nuechterlein KH, Radant AD, Schork NJ, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Tsuang DW, Tsuang MT, Turetsky BI, Braff DL. Multi-site studies of acoustic startle and prepulse inhibition in humans: initial experience and methodological considerations based on studies by the Consortium on the Genetics of Schizophrenia. Schizophr Res. 2007 May; 92(1-3):237-51. PMID: 17346930; PMCID: PMC2039885.
    73. Braff DL, Light GA, Swerdlow NR. Prepulse inhibition and P50 suppression are both deficient but not correlated in schizophrenia patients. Biol Psychiatry. 2007 May 15; 61(10):1204-7. PMID: 17161386.
      View in: PubMed
    74. Sergi MJ, Rassovsky Y, Widmark C, Reist C, Erhart S, Braff DL, Marder SR, Green MF. Social cognition in schizophrenia: relationships with neurocognition and negative symptoms. Schizophr Res. 2007 Feb; 90(1-3):316-24. PMID: 17141477.
      View in: PubMed
    75. Swerdlow NR, Light GA, Cadenhead KS, Sprock J, Hsieh MH, Braff DL. Startle gating deficits in a large cohort of patients with schizophrenia: relationship to medications, symptoms, neurocognition, and level of function. Arch Gen Psychiatry. 2006 Dec; 63(12):1325-35. PMID: 17146007.
      View in: PubMed
    76. Braff DL, Freedman R, Schork NJ, Gottesman II. Deconstructing schizophrenia: an overview of the use of endophenotypes in order to understand a complex disorder. Schizophr Bull. 2007 Jan; 33(1):21-32. PMID: 17088422; PMCID: PMC2632293.
    77. Calkins ME, Dobie DJ, Cadenhead KS, Olincy A, Freedman R, Green MF, Greenwood TA, Gur RE, Gur RC, Light GA, Mintz J, Nuechterlein KH, Radant AD, Schork NJ, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Braff DL. The Consortium on the Genetics of Endophenotypes in Schizophrenia: model recruitment, assessment, and endophenotyping methods for a multisite collaboration. Schizophr Bull. 2007 Jan; 33(1):33-48. PMID: 17035358; PMCID: PMC2632302.
    78. Schork NJ, Greenwood TA, Braff DL. Statistical genetics concepts and approaches in schizophrenia and related neuropsychiatric research. Schizophr Bull. 2007 Jan; 33(1):95-104. PMID: 17035359; PMCID: PMC2632283.
    79. Radant AD, Dobie DJ, Calkins ME, Olincy A, Braff DL, Cadenhead KS, Freedman R, Green MF, Greenwood TA, Gur RE, Light GA, Meichle SP, Mintz J, Nuechterlein KH, Schork NJ, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Swerdlow NR, Tsuang MT, Turetsky BI, Tsuang DW. Successful multi-site measurement of antisaccade performance deficits in schizophrenia. Schizophr Res. 2007 Jan; 89(1-3):320-9. PMID: 17023145.
      View in: PubMed
    80. McDowell JE, Brown GG, Lazar N, Camchong J, Sharp R, Krebs-Thomson K, Eyler LT, Braff DL, Geyer MA. The neural correlates of habituation of response to startling tactile stimuli presented in a functional magnetic resonance imaging environment. Psychiatry Res. 2006 Nov 22; 148(1):1-10. PMID: 17000088.
      View in: PubMed
    81. Light GA, Hsu JL, Hsieh MH, Meyer-Gomes K, Sprock J, Swerdlow NR, Braff DL. Gamma band oscillations reveal neural network cortical coherence dysfunction in schizophrenia patients. Biol Psychiatry. 2006 Dec 01; 60(11):1231-40. PMID: 16893524.
      View in: PubMed
    82. Swerdlow NR, Geyer MA, Shoemaker JM, Light GA, Braff DL, Stevens KE, Sharp R, Breier M, Neary A, Auerbach PP. Convergence and divergence in the neurochemical regulation of prepulse inhibition of startle and N40 suppression in rats. Neuropsychopharmacology. 2006 Mar; 31(3):506-15. PMID: 16123772; PMCID: PMC1373667.
    83. Swerdlow NR, Sprock J, Braff DL. Prepulse-elicited motor reactions do not differ between schizophrenia patients and control subjects. Behav Neurosci. 2006 Feb; 120(1):224-7. PMID: 16492135.
      View in: PubMed
    84. Hsieh MH, Swerdlow NR, Braff DL. Effects of background and prepulse characteristics on prepulse inhibition and facilitation: implications for neuropsychiatric research. Biol Psychiatry. 2006 Mar 15; 59(6):555-9. PMID: 16169529.
      View in: PubMed
    85. Light GA, Braff DL. Stability of mismatch negativity deficits and their relationship to functional impairments in chronic schizophrenia. Am J Psychiatry. 2005 Sep; 162(9):1741-3. PMID: 16135637.
      View in: PubMed
    86. Cadenhead KS, Light GA, Shafer KM, Braff DL. P50 suppression in individuals at risk for schizophrenia: the convergence of clinical, familial, and vulnerability marker risk assessment. Biol Psychiatry. 2005 Jun 15; 57(12):1504-9. PMID: 15953486.
      View in: PubMed
    87. Meincke U, Light GA, Geyer MA, Braff DL. On the waveform of the acoustic startle blink in the paradigm of prepulse inhibition - methodological and physiological aspects. Neuropsychobiology. 2005; 52(1):24-7. PMID: 15942260.
      View in: PubMed
    88. Swerdlow NR, Stephany NL, Talledo J, Light G, Braff DL, Baeyens D, Auerbach PP. Prepulse inhibition of perceived stimulus intensity: paradigm assessment. Biol Psychol. 2005 May; 69(2):133-47. PMID: 15804542.
      View in: PubMed
    89. Braff DL, Light GA, Ellwanger J, Sprock J, Swerdlow NR. Female schizophrenia patients have prepulse inhibition deficits. Biol Psychiatry. 2005 Apr 01; 57(7):817-20. PMID: 15820241.
      View in: PubMed
    90. Swerdlow NR, Talledo JA, Braff DL. Startle modulation in Caucasian-Americans and Asian-Americans: a prelude to genetic/endophenotypic studies across the 'Pacific Rim'. Psychiatr Genet. 2005 Mar; 15(1):61-5. PMID: 15722959.
      View in: PubMed
    91. Light GA, Braff DL. Mismatch negativity deficits are associated with poor functioning in schizophrenia patients. Arch Gen Psychiatry. 2005 Feb; 62(2):127-36. PMID: 15699289.
      View in: PubMed
    92. Braff DL, Light GA. The use of neurophysiological endophenotypes to understand the genetic basis of schizophrenia. Dialogues Clin Neurosci. 2005; 7(2):125-35. PMID: 16262208; PMCID: PMC3181726.
    93. Braff DL, Light GA. Preattentional and attentional cognitive deficits as targets for treating schizophrenia. Psychopharmacology (Berl). 2004 Jun; 174(1):75-85. PMID: 15118804.
      View in: PubMed
    94. Meincke U, Light GA, Geyer MA, Braff DL, Gouzoulis-Mayfrank E. Sensitization and habituation of the acoustic startle reflex in patients with schizophrenia. Psychiatry Res. 2004 Apr 15; 126(1):51-61. PMID: 15081627.
      View in: PubMed
    95. Lohr JB, Braff DL. The value of referring to recently introduced antipsychotics as "second generation". Am J Psychiatry. 2003 Aug; 160(8):1371-2. PMID: 12900294.
      View in: PubMed
    96. Green MF, Mintz J, Salveson D, Nuechterlein KH, Breitmeyer B, Light GA, Braff DL. Visual masking as a probe for abnormal gamma range activity in schizophrenia. Biol Psychiatry. 2003 Jun 15; 53(12):1113-9. PMID: 12814862.
      View in: PubMed
    97. Ellwanger J, Geyer MA, Braff DL. The relationship of age to prepulse inhibition and habituation of the acoustic startle response. Biol Psychol. 2003 Mar; 62(3):175-95. PMID: 12633977.
      View in: PubMed
    98. Schuckit MA, Kelsoe JR, Braff DL, Wilhelmsen KC. Some possible genetic parallels across alcoholism, bipolar disorder and schizophrenia. J Stud Alcohol. 2003 Mar; 64(2):157-9. PMID: 12713187.
      View in: PubMed
    99. Perry W, Minassian A, Cadenhead K, Sprock J, Braff D. The use of the Ego Impairment Index across the schizophrenia spectrum. J Pers Assess. 2003 Feb; 80(1):50-7. PMID: 12584067.
      View in: PubMed
    100. Paulus MP, Braff DL. Chaos and schizophrenia: does the method fit the madness? Biol Psychiatry. 2003 Jan 01; 53(1):3-11. PMID: 12513940.
      View in: PubMed
    101. Paulus MP, Frank L, Brown GG, Braff DL. Schizophrenia subjects show intact success-related neural activation but impaired uncertainty processing during decision-making. Neuropsychopharmacology. 2003 Apr; 28(4):795-806. PMID: 12655327.
      View in: PubMed
    102. Perry W, Feifel D, Minassian A, Bhattacharjie I, Braff DL. Information processing deficits in acutely psychotic schizophrenia patients medicated and unmedicated at the time of admission. Am J Psychiatry. 2002 Aug; 159(8):1375-81. PMID: 12153831.
      View in: PubMed
    103. Paulus MP, Hozack NE, Zauscher BE, Frank L, Brown GG, McDowell J, Braff DL. Parietal dysfunction is associated with increased outcome-related decision-making in schizophrenia patients. Biol Psychiatry. 2002 Jun 15; 51(12):995-1004. PMID: 12062884.
      View in: PubMed
    104. Cadenhead KS, Light GA, Geyer MA, McDowell JE, Braff DL. Neurobiological measures of schizotypal personality disorder: defining an inhibitory endophenotype? Am J Psychiatry. 2002 May; 159(5):869-71. PMID: 11986147.
      View in: PubMed
    105. Cadenhead KS, Braff DL. Endophenotyping schizotypy: a prelude to genetic studies within the schizophrenia spectrum. Schizophr Res. 2002 Mar 01; 54(1-2):47-57. PMID: 11853978.
      View in: PubMed
    106. McDowell JE, Brown GG, Paulus M, Martinez A, Stewart SE, Dubowitz DJ, Braff DL. Neural correlates of refixation saccades and antisaccades in normal and schizophrenia subjects. Biol Psychiatry. 2002 Feb 01; 51(3):216-23. PMID: 11839364.
      View in: PubMed
    107. Paulus MP, Hozack NE, Zauscher BE, Frank L, Brown GG, Braff DL, Schuckit MA. Behavioral and functional neuroimaging evidence for prefrontal dysfunction in methamphetamine-dependent subjects. Neuropsychopharmacology. 2002 Jan; 26(1):53-63. PMID: 11751032.
      View in: PubMed
    108. Braff DL, Geyer MA, Swerdlow NR. Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology (Berl). 2001 Jul; 156(2-3):234-58. PMID: 11549226.
      View in: PubMed
    109. Braff DL, Geyer MA, Light GA, Sprock J, Perry W, Cadenhead KS, Swerdlow NR. Impact of prepulse characteristics on the detection of sensorimotor gating deficits in schizophrenia. Schizophr Res. 2001 Apr 15; 49(1-2):171-8. PMID: 11343875.
      View in: PubMed
    110. Braff DL, Swerdlow NR, Geyer MA. Symptom correlates of prepulse inhibition deficits in male schizophrenic patients. Am J Psychiatry. 1999 Apr; 156(4):596-602. PMID: 10200740.
      View in: PubMed